{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Transplant+1+Melphalan&page=2", "query": { "intervention": "Transplant 1 Melphalan", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Transplant+1+Melphalan&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T01:41:32.648Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00325416", "title": "Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "melphalan", "type": "DRUG" }, { "name": "topotecan (TPT)", "type": "DRUG" }, { "name": "Autologous Stem Cell Rescue", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2001-11-19", "completion_date": "2018-01-30", "has_results": true, "last_update_posted_date": "2018-03-14", "last_synced_at": "2026-09-30T01:41:32.648Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00325416" }, { "nct_id": "NCT01339910", "title": "Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Myelocytic, Acute" ], "interventions": [ { "name": "Fludarabine and Busulfan", "type": "DRUG" }, { "name": "Fludarabine and Melphalan", "type": "DRUG" }, { "name": "Busulfan and Fludarabine", "type": "DRUG" }, { "name": "Busulfan and Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclophosphamide and Total Body Irradiation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 272, "start_date": "2011-06", "completion_date": "2017-10-16", "has_results": true, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-09-30T01:41:32.648Z", "location_count": 32, "location_summary": "Phoenix, Arizona • La Jolla, California • Gainesville, Florida + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01339910" }, { "nct_id": "NCT00574080", "title": "UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Interim/Maintenance Dexamethasone", "type": "DRUG" }, { "name": "Induction/Consolidation Dexamethasone", "type": "DRUG" }, { "name": "Induction/Consolidation Cisplatin", "type": "DRUG" }, { "name": "Induction/Consolidation Adriamycin", "type": "DRUG" }, { "name": "InductionConsolidation Cyclophosphamide", "type": "DRUG" }, { "name": "Induction/Consolidation Etoposide", "type": "DRUG" }, { "name": "Induction Pegfilgrastim", "type": "DRUG" }, { "name": "Transplant 1 Dexamethasone", "type": "DRUG" }, { "name": "Transplant 1 Cisplatin", "type": "DRUG" }, { "name": "Transplant 1 Adriamycin", "type": "DRUG" }, { "name": "Transplant 1 Cyclophosphamide", "type": "DRUG" }, { "name": "Transplant 1 Etoposide", "type": "DRUG" }, { "name": "Transplant 1 Melphalan", "type": "DRUG" }, { "name": "Transplant 1 and 2 Pegfilgrastim", "type": "DRUG" }, { "name": "Autologous Peripheral Blood Stem Cell Transplant (ASCT)", "type": "PROCEDURE" }, { "name": "Transplant 2 Carmustine", "type": "DRUG" }, { "name": "Transplant 2 Etoposide", "type": "DRUG" }, { "name": "Transplant 2 Cytarabine", "type": "DRUG" }, { "name": "Transplant 2 Melphalan", "type": "DRUG" }, { "name": "Transplant 2 Dexamethasone", "type": "DRUG" }, { "name": "Transplant 1 and 2 Bortezomib", "type": "DRUG" }, { "name": "Transplant 1 and 2 Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2006-07", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-09-30T01:41:32.648Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00574080" }, { "nct_id": "NCT00498316", "title": "Cord Blood Expansion on Mesenchymal Stem Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome", "Leukemia" ], "interventions": [ { "name": "Cord Blood Infusion", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "ATG", "type": "OTHER" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "80 Years", "sex": "ALL", "summary": "1 Year to 80 Years" }, "enrollment_count": 98, "start_date": "2007-07-03", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2020-02-28", "last_synced_at": "2026-09-30T01:41:32.648Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00498316" }, { "nct_id": "NCT00043979", "title": "Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "F-18 Fluorodeoxyglucose", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell donation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "5 Years to 35 Years" }, "enrollment_count": 60, "start_date": "2002-09-19", "completion_date": "2011-12-14", "has_results": true, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-09-30T01:41:32.648Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043979" }, { "nct_id": "NCT01453088", "title": "Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 63, "start_date": "2010-06-24", "completion_date": "2022-05-01", "has_results": true, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-09-30T01:41:32.648Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01453088" }, { "nct_id": "NCT01729091", "title": "Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Leukemia", "Plasma Cell Myeloma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Elotuzumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Natural Killer Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Umbilical Cord Blood-Derived Lymphocyte Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 72, "start_date": "2013-06-10", "completion_date": "2024-06-25", "has_results": true, "last_update_posted_date": "2025-05-09", "last_synced_at": "2026-09-30T01:41:32.648Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01729091" }, { "nct_id": "NCT00081939", "title": "UARK 2003-33, Total Therapy III", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Velcade", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 303, "start_date": "2004-01", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-10-17", "last_synced_at": "2026-09-30T01:41:32.648Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081939" }, { "nct_id": "NCT03615105", "title": "Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoid Leukemia (ALL)", "Acute Myeloid Leukemia (AML)", "Chronic Myeloid Leukemia (CML)", "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Hyperfractionated total body irradiation", "type": "RADIATION" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "HPC(A) stem cell allograft", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Rabbit antithymocyte globulin", "type": "DEVICE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE", "DEVICE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 9, "start_date": "2018-07-25", "completion_date": "2024-03-06", "has_results": true, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-09-30T01:41:32.648Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03615105" }, { "nct_id": "NCT00083551", "title": "UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Thalidomide", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Recombinant GM-CSF", "type": "DRUG" }, { "name": "Interferon-alpha-2b", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 668, "start_date": "1998-08", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2015-11-23", "last_synced_at": "2026-09-30T01:41:32.648Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083551" } ] }